Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Boston Scientific Corporation (BSX) Price & Performance

Allbirds IncTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Boston Scientific Corporation — how do they compare? Allbirds Inc trades at $2.6 (market cap $22.68M), while Boston Scientific Corporation trades at $51.15 (market cap $71.46B). The key difference: Boston Scientific Corporation is far larger — about 3150.8× Allbirds Inc's market cap, and Boston Scientific Corporation is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.

BIRDBSX
Market Cap
$22.68M$71.46B
Sector
Consumer CyclicalHealth
52-Week High
$16.99$108.14
52-Week Low
$2.21$42.63
Enterprise Value
$41.54M$83.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $2.53, up 5.42% with a bullish technical signal despite mixed earnings. The company completed a strategic pivot from footwear to AI infrastructure in June 2026, appointing former AWS executive Nadia Carlsten as CEO. While revenue declined to $152M in 2025 with a -53.4% net margin, the P/S ratio of 0.15 suggests potential undervaluation relative to AI sector peers.

The outlook hinges on successful execution of the AI infrastructure strategy, though significant execution risks remain given negative cash flows and lack of profitability. Analyst consensus shows cautious optimism with 21% buy ratings amid high institutional hold positions. Near-term catalysts include new board appointments and AI business development progress.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX